Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.57 |
| ▸ | AXL | P30530 | 3/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8258473 | 0.86 | CDK8 (0.57) | CDK8AXLCCNT1CCNA2CDK2 | |
| SCHEMBL12764154 | 0.77 | CDK8 (0.56) | CDK8AXLAAK1PDGFRBPDGFRA | |
| SCHEMBL12764150 | 0.76 | CDK8 (0.57) | CDK8AXLCCNT1CCNA2CDK2 | |
| SCHEMBL8249652 | 0.76 | MAPK8 (0.60) | CDK8AXLAAK1TNIKGSK3B | |
| SCHEMBL15799266 | 0.74 | CDK8 (0.70) | CDK8AXLCCNT1CCNA2CDK2 | |
| SCHEMBL15779522 | 0.74 | MAP3K11 (0.58) | AAK1 | |
| SCHEMBL3761982 | 0.74 | DYRK1A (0.75) | CDK8AXLCCNT1CCNA2CDK2 | |
| SCHEMBL12764153 | 0.72 | AXL (0.46) | CDK8AXLAAK1TNIKGSK3B | |
| SCHEMBL8321343 | 0.72 | CDK8 (0.70) | CDK8AXLCCNT1CCNA2CDK2 | |
| SCHEMBL15799643 | 0.72 | CDK8 (0.70) | CDK8AXLCCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | CDK8 1731/4885AXL 2467/4885CCNT1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.